Marketdash
Back to News

Cramer's Housing Reality Check: 'No One's Buying Homes Here'

MarketDash Editorial Team
16 days ago
Jim Cramer delivered his signature rapid-fire stock takes on Thursday, dismissing Rocket Companies amid sluggish housing demand while acknowledging he missed the boat on Regeneron. He also weighed in on the Netflix versus FuboTV debate.

Jim Cramer didn't mince words during Thursday's "Mad Money Lightning Round" on CNBC, delivering his characteristically blunt takes on several stocks that crossed his desk.

Streaming Showdown

When it comes to streaming video, Cramer made his preference clear: Netflix Inc. (NFLX) over fuboTV Inc. (FUBO). This comes even as FuboTV reported mixed but somewhat encouraging quarterly results on November 3. The sports-first live TV streaming platform saw revenue slip 2.3% year-over-year to $377.20 million, but still managed to beat analyst expectations of $361.33 million for the third quarter of 2025.

Housing Market Reality

Cramer's assessment of Rocket Companies, Inc. (RKT) was even more direct. "No one's buying homes here," he said, cutting straight to the heart of the mortgage lender's challenge in the current environment.

That pessimism stands in contrast to Rocket's recent earnings performance. On October 30, the company reported quarterly earnings of 7 cents per share, topping the Street estimate of 5 cents. Revenue came in at $1.78 billion, comfortably ahead of the $1.66 billion consensus.

Regeneron Regrets

Cramer acknowledged he should have been championing Regeneron Pharmaceuticals, Inc. (REGN) earlier. "It's coming right back right now," he noted, as the biotech stock gained momentum.

The timing makes sense. The U.S. Food and Drug Administration recently approved Regeneron's Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following retinal vein occlusion (RVO), offering dosing flexibility with up to every 8-week intervals after an initial monthly period.

Market Movement

Thursday's trading reflected the mixed sentiment. Rocket Companies shares dipped 3.6% to settle at $16.17, while Regeneron Pharmaceuticals surged 5% to close at $737.00. Netflix declined 3.9% to settle at $105.67, and FuboTV fell 5% to close at $3.24.

Back to News

Cramer's Housing Reality Check: 'No One's Buying Homes Here'

MarketDash Editorial Team
16 days ago
Jim Cramer delivered his signature rapid-fire stock takes on Thursday, dismissing Rocket Companies amid sluggish housing demand while acknowledging he missed the boat on Regeneron. He also weighed in on the Netflix versus FuboTV debate.

Jim Cramer didn't mince words during Thursday's "Mad Money Lightning Round" on CNBC, delivering his characteristically blunt takes on several stocks that crossed his desk.

Streaming Showdown

When it comes to streaming video, Cramer made his preference clear: Netflix Inc. (NFLX) over fuboTV Inc. (FUBO). This comes even as FuboTV reported mixed but somewhat encouraging quarterly results on November 3. The sports-first live TV streaming platform saw revenue slip 2.3% year-over-year to $377.20 million, but still managed to beat analyst expectations of $361.33 million for the third quarter of 2025.

Housing Market Reality

Cramer's assessment of Rocket Companies, Inc. (RKT) was even more direct. "No one's buying homes here," he said, cutting straight to the heart of the mortgage lender's challenge in the current environment.

That pessimism stands in contrast to Rocket's recent earnings performance. On October 30, the company reported quarterly earnings of 7 cents per share, topping the Street estimate of 5 cents. Revenue came in at $1.78 billion, comfortably ahead of the $1.66 billion consensus.

Regeneron Regrets

Cramer acknowledged he should have been championing Regeneron Pharmaceuticals, Inc. (REGN) earlier. "It's coming right back right now," he noted, as the biotech stock gained momentum.

The timing makes sense. The U.S. Food and Drug Administration recently approved Regeneron's Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following retinal vein occlusion (RVO), offering dosing flexibility with up to every 8-week intervals after an initial monthly period.

Market Movement

Thursday's trading reflected the mixed sentiment. Rocket Companies shares dipped 3.6% to settle at $16.17, while Regeneron Pharmaceuticals surged 5% to close at $737.00. Netflix declined 3.9% to settle at $105.67, and FuboTV fell 5% to close at $3.24.